Unfractionated heparin, time for a change?

Irish Medical Journal

Volumn 92, Issue 3, 1999, Pages 302-306

  Ridgway, P F ^a   Crosbie, J ^a   Hinedi, K A ^a   Ghadban, W ^a   Kelly, A ^a   O'Donnell, R ^a   Hollingsworth, J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; HUMAN; THROMBOEMBOLISM; THROMBOPHLEBITIS;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0033111481     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Prandoni P, Lensing AWA, Büller HR et al: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339:441-51
2. Hull RD, Raskob GE, Pineo GF, Green D et al: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326:975-82.J.
3. Muir J, Hirsh J, Weitz J et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997; 89(9):3236-42.
4. Siragusa S, Cosmi B, Piovella F et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100(3):269-77.
5. Warkentin T, Levine M, Hirsh J et al. Heparin induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332(20):1330-5.
6. Lensing A, Prins M, Davidson B and Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis. Arch Intern Med 1995;155(6):601-7.
7. Rosenberg RD, Damus PS: The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248:6490, Bjork I.
8. Lindahl U: Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48:161.
9. Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992;79:1-17.
10. Andersson LO, Barrowdiffe TW, Holmer E, Johnson EA, Soderstrom G: Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralisation in plasma. Thromb Res 1979; 115:531.
11. Carter BL: Therapy of acute thromboembolism with heparin and warfarin. Clin Pharm 1991; 10:503-18.
12. How to anticoagulate. Drug and therapeutics bulletin 1992; vol 30: no 20.
13. Hull RD, Raskob GE, Rosenbloom D, et al: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260-4.
14. Gallus AS, Jackaman J, Tillet J, Mills W, Wycherley A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism9 Lancet 1986; 2:1293-6.
15. Hollingsworth JA, Rowe BH, Brisebois FJ, Thompson PR, Fabris LM: The successful application of a heparin nomogram in a community hospital Arch Intern Med 1995.
16. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA : Relation Between the Time to Achieve the Lower Limit of the APTT Therapeutic Range and Recurrent Venous Thromboembolism During Heparin Therapy for Deep Venous Thrombosis : Archives of Internal Medicine 1997; 157:2562-2568.
17. Ten Cate et al. Personal communication.
18. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for deep vein thrombosis. N Engl J Med 1996; 334:677-81.
19. Koopman MMW, Pradoni P, Piovella F, et al. Treatment of venous thrombosis with unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med 1996; 334:682-7.